Trials / Completed
CompletedNCT02797821
Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
A Phase 2a, Randomized, Multicenter, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of asfotase alfa in adult participants with pediatric-onset HPP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Asfotase alfa |
Timeline
- Start date
- 2016-06-06
- Primary completion
- 2017-06-21
- Completion
- 2017-06-21
- First posted
- 2016-06-14
- Last updated
- 2019-09-17
- Results posted
- 2018-07-10
Locations
4 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT02797821. Inclusion in this directory is not an endorsement.